Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ranosidenib · HMPL-306

Small molecule · Inhibitor of isocitrate dehydrogenase 1 (mutant) (IDH1) and isocitrate dehydrogenase 2 (mutant) (IDH2) · developed by Hutchmed

Phase 3 Most advanced trial
HCM Developer
4 Registered trials

What is Ranosidenib?

Ranosidenib (HMPL-306) is an orally bioavailable small molecule that inhibits mutant forms of IDH1 and IDH2, blocking the formation of the oncometabolite 2-hydroxyglutarate from alpha-ketoglutarate. It is being studied in acute myeloid leukemia, IDH-mutant gliomas, and a mass balance study.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
HMPL-306, 100 µCi [14C] HMPL-306
Drug type
Small molecule
Targets
isocitrate dehydrogenase 1 (mutant) (IDH1), isocitrate dehydrogenase 2 (mutant) (IDH2)
Mechanism
Inhibitor of isocitrate dehydrogenase 1 (mutant) (IDH1) and isocitrate dehydrogenase 2 (mutant) (IDH2)
Pathways
2-hydroxyglutarate formation, cellular differentiation, cellular proliferation
Therapy area
Oncology
Developer
Hutchmed (HCM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
PC64OXS2C2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07912398 Phase 3 Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation Not yet recruiting HCM
NCT06387069 Phase 3 Acute Myeloid Leukemia Recruiting HCM
NCT07025018 Phase 1 Gliomas Harboring IDH1 and/or IDH2 Mutations Recruiting HCM
NCT06671873 Phase 1 Mass Balance Study Completed HCM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid LeukemiaGliomas Harboring IDH1 and/or IDH2 MutationsMass Balance Study

Other drugs acting on IDH1 / IDH2

More from Hutchmed

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the HCM page.

Follow HCM, the company behind Ranosidenib

See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HCM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.